Combining pharmacophore, QSAR and docking screens uncovers a submicromolar histamine H3 receptor binder from a CNS library
- Structure-based and ligand-based pharmacophore models were built from the H3R crystal structure and known inhibitors, then checked retrospectively against decoys alongside a QSAR model.
- These models screened a commercial CNS-focused, BBB-oriented library; docking, consensus scoring and QSAR filtering narrowed it to a short list of candidates.
- Radioligand displacement testing confirmed one submicromolar binder and several low micromolar ones, showing the combined workflow yields real, experimentally confirmed hits.
💡 Points Based on the abstract
Nothing methodologically new here; it's a standard pharmacophore-QSAR-docking funnel, so the interesting question is the hit rate against a plain docking-only baseline, which isn't shown. Decoy-based retrospective checks are easy to flatter. Still, wet-lab confirmation from a purchasable, BBB-aware library is useful, though I'd want novelty versus known H3 chemotypes first.